LIFE SAVING DRUGS PROGRAM EXPERT PANEL

SEVENTH MEETING: 22-23 October 2020

**AGENDA**

# Standing business

* 1. Welcome & apologies
  2. Declaration of potential or actual Conflict of Interest
  3. Correspondence
  4. Report from the Secretariat

# Reviews of existing LSDP medicines

TRANCHE 1 – **finalise outcomes** of reports

* 1. Agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®) for treatment of Fabry disease
  2. Imiglucerase (Cerezyme®), velaglucerase (VPRIV®) and taliglucerase (Elelyso®) for treatment of Gaucher disease

TRANCHE 2 – **finalise outcomes** of reports

* 1. Eculizumab (Soliris®) for treatment of Paroxysmal Nocturnal Haemoglobinuria
  2. Idursulfase (Elaprase®) for treatment of Mucopolysaccharidosis Type II
  3. Alglucosidase alfa (Myozyme®) for treatment of Pompe disease

TRANCHE 3 – review of **final** reports

* 1. Laronidase (Aldurazyme®) for treatment of Mucopolysaccharidosis type I
  2. Galsulfase (Naglazyme®) for treatment of Mucopolysaccharidosis type VI
  3. Nitisinone (Orfadin®) for Hereditary Tyrosinaemia type I

# Applications for new LSDP medicines

# Other business